Controversies in regenerative medicine: should knee joint osteoarthritis be treated with mesenchymal stromal cells?

Simple item page
dc.coverageDOI: 10.22203/eCM.v043a09
dc.creatorOssendorff, R.
dc.creatorWalter, S. G.
dc.creatorSchildberg, F. A.
dc.creatorKhoury, M.
dc.creatorSalzmann, G. M.
dc.date2022
dc.date.accessioned2025-11-18T19:49:20Z
dc.date.available2025-11-18T19:49:20Z
dc.description<p>Knee joint osteoarthritis is a complex immunological and degenerative disease. Current treatment strategies fail to alter its progression. Mesenchymal stromal cell (MSC) therapy for osteoarthritis has been object of research for more than 30 years. The aim of MSC therapy is intended to be holistic, with regeneration of all affected knee joint structures. The paracrine effect of the MSC secretome has been shown to be central for the regenerative capacity of MSCs. Activation of local knee-joint-specific MSCs leads to an immunomodulatory, anti-catabolic, anti-apoptotic and chondrogenic stimulus. Preclinical models have demonstrated the symptom-and disease-modifying effects of MSC therapy. At the bedside, there is evidence that autologous and allogeneic MSC therapy shows significant improvement in symptom-modifying and functional outcome. Despite this, a variety of contradictory clinical outcomes are available in the literature. The effectiveness of MSC therapy is still unclear, although there have been promising results. Regarding the diversity of cell sources, isolation, culture protocols and other factors, a comparison of different studies is difficult. Clinical translation of disease-modifying effects has not yet been shown. This narrative review presents a controversial overview of the current preclinical and clinical studies on MSC therapy in knee joint osteoarthritis.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/258ff3bd-838b-4a06-973a-6bfa9734ffeb
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/56024
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.43 (2022) date: 2022-03-17 p.98-111
dc.subjectMesenchymal stem cell
dc.subjectcartilage repair
dc.subjectchondrogenesis
dc.subjectknee joint
dc.subjectknee joint osteoarthritis
dc.subjectmesenchymal stromal cell
dc.subjectosteoarthritis
dc.titleControversies in regenerative medicine: should knee joint osteoarthritis be treated with mesenchymal stromal cells?eng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
PURE